Slides
Page 1
Investor PresentationFull Year 2026 ResultsAugust 2026Treatment focused.Technology driven.
Page 2
Disclaimer © August 2026 SomnoMed 2 This document has been prepared as a summary only and does not contain all information about SomnoMed Limited’s (the Company’s) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document should be read in conjunction with any public announcements and reports (including financial reports and disclosure documents) released by the Company. The securities issued by the Company are considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will bepaid on the Shares or that there will be an increase in the value of the Shares in the future.Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning estimates of future sales, expected revenues and costs, statements relating to the continued advancement of the Company’s operations and other statements which are not historical facts. When used in this document, and on other published information of the Company, the words such as “aim”, “could”, “estimate”, “expect”, “intend”, “target”, “forecast”, “future”, “will”, “may”, “potential”, “should” and similar expressions are forward-looking statements.Although the company believes that its expectations reflected in the forward-looking statements are reasonable, such statements involve risk and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Various factors could cause actual results and projections of future performance to differ from these forward-looking statements as a result of known and unknown risks, uncertainties and other factors not anticipated by the Company or disclosed in the Company’s published material. Many of these factors are beyond the control of the Company Limited and may involve subjective judgement and assumptions as to future events, which may or may not be correct.The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this document.Recipients of this document should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position.
Page 3
Company Highlights
Page 4
SomnoMed is the global market leader in oral appliance therapy 4 A world where our oral appliance therapy is the standard of care for obstructive sleep apnea treatment (OSA).VISIONAs the global leader in oral appliance therapy (OAT), we set the standard for outcomes, innovation and patient experience – driving the transformation of sleep medicine worldwide.MISSIONLARGE AND GROWING MARKETIncreasing OSA consumer awareness, growth in GLP-1 drugs, and demand for CPAP alternatives is growing the OAT market.Significant total addressable patient market with ~1 Billion individuals suffering from OSA globally.Total potential customer market of 700K+ dentists in key regions © August 2026 SomnoMedSomnoMed is the global market leader in oral appliances for OSA and well positioned to drive growth. With over 1 million patients treated worldwide and leading positions across multiple geographies, SomnoMed is well positioned to capitalise on the market opportunity and drive growth
Page 5
Financial HighlightsStrong foundation established to deliver on strategic initiatives 5 •EBITDA1- Up 19% to $10.9m, 9.6% margin •Revenue- Up 3% to $114.5m, led by North America (NAM)Robust Balance Sheet•Positive operating cash flow before and after leases of +$8.3m and +$5.2m•Cash positionmaintained at $17.2m (net cash $16.8m)Solid Financial Results (FY26)Disciplined Cost / Capital Management• FY26 cost discipline contributing to double digit EBITDA growth •Over 50% of Capex spend driven by growth initiatives and manufacturing capacity investment1 EBITDA excludes leases payments ($3.1m), share/option expenses ($3.6m), unrealised foreign exchange gain/(loss) ($1.1m), one-off costs ($0.7m - tranche 3 restructure) and discontinued operations (nil).
Page 6
Operational HighlightsStrong foundation established to deliver on strategic initiatives 6 Experienced LeadershipExecutive management update for FY26 and FY27 to date:•Karen Borg – sole CEO•Greg Knight – COO•Nathan Minnich – CMOWith thanks to Amrita Blickstead –stepped down as Co-CEO 27 July 2026Production ImprovementsManufacturing capacity expanded by over 20% in FY26 and over 40% across 2 yearsManufacturing productiontimes improved by over 50% across 2 years~50%1of OSA patients have co-existing sleep bruxismVirtusdesigned to target patients with OSA and sleep bruxismControlled market releaseunderway globallyProduct Innovation(Virtus) 1 Li D, Kuang B, Lobbezoo F, de Vries N, Hilgevoord A, Aarab G. A large scale polysomnographic study involving 914 adults with OSA published in March 2023 found that sleep bruxism is highly prevalent in adults with obstructive sleep apnea. Journal of Clinical Sleep Medicine. 2023;19(3):443-451.
Page 7
FY2026 Results
Page 8
$4.8m$5.2mFY25FY26$9.2m$10.9mFY25FY26$111.5m$114.5mFY25FY26© August 2026 SomnoMed88 Financial Highlights 1 EBITDA excludes leases payments ($3.1m), share/option expenses ($3.6m), unrealised foreign exchange gain/(loss) ($1.1m), one-off costs ($0.7m - tranche 3 restructure) and discontinued operations (nil).2Constant currency calculated using FY25 prior year rates of 0.65 USD/AUD and 0.59 EUR/AUD. Approximately 95% of the Company’s revenues are in non-AUD currencies.. +3%Revenue growth• 1HFY revenue (up 13% and 8% constant currency (CC)2) driven by North America and Europe performance.• 2HFY26 revenue (down 7% and 1% in CC) impacted by a change in Europe market dynamics and appreciation of the Australian dollar. EBITDA1growth• EBITDA1and margin improvement on higher revenue, improved gross margin and disciplined operating cost management.• Increase in operating cash flow after leases, reflective of FY26 revenue growth and disciplined costs management Positive operating cash flowafter leases+19%+8%8.2% margin9.6% margin
Page 9
$4m$3m$7m$4m$3m$7m1H 2H FYFY25FY26-3%$22m$21m$43m$24m$21m$46m1H 2H FYFY25FY26$28m$33m$61m$33m$29m$62m1H 2H FYFY25FY26 Regional Revenue Highlights © August 2026 SomnoMed 9+17%+11%+1%-1%+6%+1%-13%-4%+11%+12%+10%-1%-9%+8%-2%-4%0%Constant Currency Growth Europe Constant Currency Growth North America Constant Currency Growth APAC • Our primary growth region• Performed strongly, in line with expectations• Our most mature region• Following a strong 1H, the region faced reimbursement and referral path headwinds that negatively impacted growth in 2H• Our first commercial region• Cost of living pressures impacted patient demand across the non-reimbursed markets
Page 10
%FY25FY26$m+3%111.5 114.5Revenue+5%66.7 70.0Gross profit+0%(22.9) (23.0) Sales and marketing expenses+3%(18.4) (19.0) Administrative and other expenses+10%25.428.1 Operating profit +5%(16.2) (17.1) Corporate, research and business development expenses+19%9.2 10.9 EBITDA1 -10%(3.1) (2.8) Depreciation and amortisation expenses+4%(3.0)(3.1)Leases-100%(0.1)-Interest+45%(3.8) (5.5) Other2 -40%(0.8) (0.5) Loss before tax-19%(2.7)(2.2) Tax-23%(3.5)(2.7)Net loss after tax% pointFY25FY26Key metrics+1.270.3%71.5%MAS (device) gross margin %+1.259.9%61.1%Group gross margin %+1.48.2%9.6%EBITDA1margin Profit or Loss Summary © August 2026 SomnoMed 101 EBITDA excludes leases payments ($3.1m). 2Other represents share/option expenses ($3.6m), unrealised foreign exchange gain/(loss) ($1.1m), one-off costs ($0.7m - tranche 3 restructure) and discontinued operations (nil).3 Figures may not sum due to rounding.Other2• Increase primarily from higher share-based payment expenses (non-cash).Margins• Stronger margins across all key metrics despite Europe market dynamics and FX headwinds.Tax• Tax expenses represent operating profits across Europe and North America.
Page 11
Balance Sheet Summary 11 30 June 202530 June 2026$m17.317.2Cash and cash equivalents18.514.5Trade and other receivables7.47.4Inventories7.07.6Property, plant and equipment21.522.4Intangible assets6.94.7Right of use asset2.41.3Deferred tax assets81.075.0Total assets19.516.4Trade and other payables0.80.4Borrowings5.34.7Provisions1.81.0Current tax liabilities7.25.0Lease liabilities34.627.6Total liabilities46.447.4Net assetsBorrowings• Residual debt represents European government backed borrowings.© August 2026 SomnoMed Working capital • Improvement in collections. • Lower prepayments and costs accruals.1 Figures may not sum due to rounding.
Page 12
Cash Flow Summary 121 EBITDA excludes leases payments ($3.1m), share/option expenses ($3.6m), unrealised foreign exchange gain/(loss) ($1.1m), one-off costs ($0.7m - tranche 3 restructure) and discontinued operations (nil). 2 Lease cost of $3.1m presented under financing cash flow for statutory accounts. 3 Figures may not sum due to rounding. FY25FY26$m9.210.9EBITDA1 (0.1)(0.4)Movement in working capital and other non-cash(0.8)(1.4)Tax paid(0.5)(0.9)One-off expenses7.88.3Operating cash flow (before leases)(3.0)(3.1)Payment of finance leases2 4.85.2Operating cash flow (after leases)(1.6)(2.5)Payments for intangible assets(2.4)(3.3)Payments for property, plant and equipment(4.0)(5.7)Investing cash flow0.8(0.6)Free cash flow -2.0Proceeds from repayment of loan by Employee Share Trust(0.3)(0.3)Repayment of borrowings(0.3)1.6Financing cash flow0.41.1Net cash flow before exchange rate adjustments0.7(1.2)Exchange rate adjustments1.1(0.1)Net cash flow One-off expenses• Related to cash settlement of prior year and current year one-off cost provisions.Investing• Continued investments in manufacturing infrastructure and R&D. Employee share trust transaction• Net $2.0m of proceeds from repayment of loan in relation to 2.86m shares by SomnoMed’semployee share trust. © August 2026 SomnoMedFX• Reflects appreciation of AUD against key currencies (primarily USD and EUR) in FY26. Approximately 95% of the Company’s revenues are in non-AUD currencies.
Page 13
Strategy and Outlook
Page 14
Market Dynamics 14© August 2026 SomnoMed CPAP failures: up to 50% of patients discontinue therapy1OAT competitors: growth in lower cost products & clinical differentiation challengesPharma entrants: GLP-1s / emerging drugs are driving patient growthNeurostimulation: newer, high-cost, invasive surgical procedures are entering the marketDTC models: emerging but nascent 1. Drigo R, Ballarin A, Menzella F, et al. Nature and Science of Sleep. 2025;17:357-363. doi:10.2147/NSS.S501341
Page 15
From Turnaround to Sustainable Growth 15 Financial: cleared debt, generated positive cashflow People and culture: investment in talent Operational: capacity increase to improve turnaround timesFY24 - FY26 FY27 - FY30 1 EBITDA excludes leases payments, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations. Financial & Operational TurnaroundGrowth & Profitability ObjectivesReturn to double digit revenue growthProgressively expand EBITDA1margins through scale and efficiency gainsOrganic growth-focus; consideration of small-scale acquisition opportunities© August 2026 SomnoMed
Page 16
Market-Leading Portfolio Tailored by Region 16 VirtusFlex & Fusion®Herbst Advance Elite® Designed for US ReimbursementMedicare ReimbursedNext-Generation OAT InnovationGlobal Controlled Release UnderwayEstablished European PlatformsReimbursed across Key European Markets © August 2026 SomnoMed
Page 17
Commercial Focus to Drive Growth 17 • Product innovation targeting most accessible Centre for Medicare and Medicaid Services (CMS) codes• Strategies implemented to drive demand within specific key customer cohortsNorth AmericaEurope• Continued engagement with GLP-1 manufacturer• Investigating product line extensions for non-reimbursed environmentAPAC• Restructured commercial and operational leadership to improve customer experience• Developed dedicated product strategies to respond to the changing environment• Application underway to improve reimbursement in key market © August 2026 SomnoMed
Page 18
A Bold Vision to Drive Growth FY27 & Beyond 18 • GLP-1s and other pharma-led trends• Connected Care and home diagnostics• CPAP failures1. Capture the Growing Patient Pool2. Accelerate New Products Aligned to Market Needs• Clinician connectivity & engagement• Expanded reimbursement framework3. Expand Referring and Treating CliniciansHAE®, Classic, Flex, Fusion®Existing:VirtusNew:Connected Care / Rest Assure®Future:Strategic roadmap to be detailed at the upcoming Annual General Meeting. © August 2026 SomnoMed
Page 19
FY27 – Outlook © August 2026 SomnoMed 191 EBITDA excludes leases payments, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations. vs. $0.6m FY24Key assumptions and sensitivities:1. Continued NAM growth and EU stabilisation2. Successful global adoption of Virtus - H2 FY273. Stable EBITDA1margins while investing to support future growth4. FX movementsAs announced on 27 July 2026, the Company is targeting high single digit revenue growth in FY27 while maintaining EBITDA1margins consistent with FY26. FY27 guidance range is expected to be issued as part of the 2026 Annual General Meeting.Setting the stage for growth
Page 20
Q&A
Page 21
For further information please contact:Investor Relations:IR@somnomed.com.au 21 Thank You © August 2026 SomnoMed